Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Citi (C) Posts Strong Earnings, Stuffed Crust Strengthens DPZ, JNJ Slides
10:01am, Tuesday, 14'th Oct 2025
While big banks as a group posted strong earnings, Diane King Hall notes Citigroup (C) as a standout. She talks about how stronger IPO and dealmaking markets added muscle for the company.
Johnson & Johnson reports Q3 beat, plans orthopaedics spin-off
09:54am, Tuesday, 14'th Oct 2025
Johnson & Johnson (NYSE:JNJ) posted third-quarter revenue and earnings that beat Wall Street estimates, driven by strength in its pharmaceuticals and medical devices businesses. The healthcare giant r
Johnson & Johnson Q3 Earnings Surprise, Icotrokinra Shines Again
08:58am, Tuesday, 14'th Oct 2025
Today, Johnson & Johnson released its financial results for Q3 2025, which once again stunned Wall Street. So, sales of Rybrevant/Lazcluze, the 'diamond' in its oncology franchise, reached $198 millio
Johnson & Johnson to spin off orthopedics unit after raising 2025 sales forecast
08:56am, Tuesday, 14'th Oct 2025
Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings and revealed plans to spin off its orthopedics business into a standalone comp
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
08:51am, Tuesday, 14'th Oct 2025
Johnson & Johnson (NYSE:JNJ) on Tuesday reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $2.75.
Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates
08:31am, Tuesday, 14'th Oct 2025
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.8 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago.
Johnson & Johnson's stock heads for a record after a profit beat and plans for another spinoff
07:44am, Tuesday, 14'th Oct 2025
Johnson & Johnson's stock rose toward a record after a beat-and-raise earnings report and announcement of plans to separate its orthopedics business.
J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth
07:33am, Tuesday, 14'th Oct 2025
Johnson & Johnson chairman and CEO Joaquin Duato joins 'Squawk Box' to discuss the company's quarterly earnings results, adding warning labels to its multiple myeloma treatment Carvykti, the decision
J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains
06:32am, Tuesday, 14'th Oct 2025
Johnson & Johnson raised its full-year sales outlook as it posted gains in both its prescription-drug and medical-device businesses in the latest quarter.
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2025
06:30am, Tuesday, 14'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Q4 dividend.
J&J to spin off orthopedics business, raises full-year forecast
06:26am, Tuesday, 14'th Oct 2025
Johnson & Johnson on Tuesday said it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff since 20
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
06:21am, Tuesday, 14'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (the “Company”) (NYSE: JNJ) today announced the Company's intent to separate its Orthopaedics business to enhance the strategic and operatio
Johnson & Johnson Reports Q3 2025 Results; Raises 2025 Sales Outlook
06:20am, Tuesday, 14'th Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2025. “Johnson & Johnson delivered another strong performance in the third quarter fuele
The planned separation is the latest move by J&J to slim down in recent years and focus on faster-growing businesses.
Big Money Move: Investment Manager Buys $6.9 Million Worth of Johnson & Johnson Shares, According to Recent Filing
06:47pm, Monday, 13'th Oct 2025
Cyndeo Wealth Partners, LLC purchased 40,238 shares of Johnson & Johnson (JNJ 0.09%) for an estimated $6.89 million during the quarter ended September 30, 2025, according to its October 10, 2025 SEC f
